WO2002068579A3 - Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof - Google Patents

Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof Download PDF

Info

Publication number
WO2002068579A3
WO2002068579A3 PCT/US2002/000284 US0200284W WO02068579A3 WO 2002068579 A3 WO2002068579 A3 WO 2002068579A3 US 0200284 W US0200284 W US 0200284W WO 02068579 A3 WO02068579 A3 WO 02068579A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
kits
transcripts
majority
acid arrays
Prior art date
Application number
PCT/US2002/000284
Other languages
French (fr)
Other versions
WO2002068579A2 (en
Inventor
Craig J Venter
Mark Adams
Peter W D Li
Eugene W Myers
Original Assignee
Pe Corp Ny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pe Corp Ny filed Critical Pe Corp Ny
Priority to AU2002255478A priority Critical patent/AU2002255478A1/en
Publication of WO2002068579A2 publication Critical patent/WO2002068579A2/en
Publication of WO2002068579A3 publication Critical patent/WO2002068579A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is based on the sequencing and assembly of the human genome. The present invention provides the primary nucleotide sequence of the coding portion of the human genome in the form of a series of transcript sequences with accompanying exon information. This information can be used to generate nucleic acid detection reagents and kits such as nucleic acid arrays, and for other uses.
PCT/US2002/000284 2001-01-10 2002-01-10 Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof WO2002068579A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002255478A AU2002255478A1 (en) 2001-01-10 2002-01-10 Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75669601A 2001-01-10 2001-01-10
US09/756,696 2001-01-10

Publications (2)

Publication Number Publication Date
WO2002068579A2 WO2002068579A2 (en) 2002-09-06
WO2002068579A3 true WO2002068579A3 (en) 2003-07-31

Family

ID=25044658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000284 WO2002068579A2 (en) 2001-01-10 2002-01-10 Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof

Country Status (2)

Country Link
AU (1) AU2002255478A1 (en)
WO (1) WO2002068579A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101061016B1 (en) 2008-09-17 2011-08-31 강원대학교산학협력단 Polypeptides or fusion proteins thereof having an inhibitory activity against growth of cancer cells and preventive or treating activity against inflammatory diseases
KR101062167B1 (en) 2008-10-23 2011-09-05 사회복지법인 삼성생명공익재단 A composition for treating cancer comprising a Vir 2.2 inhibitor
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9127268B2 (en) 2009-12-11 2015-09-08 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018412A1 (en) * 2000-08-28 2002-03-07 Human Genome Sciences, Inc. 17 human secreted proteins
WO2001066690A2 (en) * 2000-03-06 2001-09-13 Smithkline Beecham Corporation Novel compounds
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1666497A3 (en) * 2000-06-02 2006-06-21 Genentech, Inc. Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer
WO2002002627A2 (en) * 2000-06-30 2002-01-10 Zymogenetics, Inc. Interferon-like protein zcyto21
US20040254348A1 (en) * 2000-07-12 2004-12-16 Shuji Hinuma Novel polypeptide and dna thereof
JP4503801B2 (en) * 2000-09-08 2010-07-14 独立行政法人科学技術振興機構 Novel human cancer / testis antigen and its gene
WO2002052005A1 (en) * 2000-12-22 2002-07-04 Kazusa Dna Research Institute Foundation Novel genes and proteins encoded thereby
CA2437021A1 (en) * 2001-02-01 2002-08-08 Mochida Pharmaceutical Co., Ltd. Adiponectin-associated protein
EP1434783A4 (en) * 2001-03-16 2006-06-07 Lilly Co Eli Lp mammalian proteins; related reagents
CA2441654A1 (en) * 2001-03-29 2002-10-10 Incyte Genomics, Inc. Cytoskeleton-associated proteins
DE60230051D1 (en) * 2001-04-10 2009-01-08 Agensys Inc NUCLEIC ACID AND CORRESPONDING PROTEIN NAMELY 121P2A3 FOR THE TREATMENT AND DETECTION OF CANCER
US7309760B2 (en) 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
CA2444504A1 (en) * 2001-04-26 2002-11-07 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
AUPR470101A0 (en) * 2001-05-02 2001-05-24 Murdoch Childrens Research Institute, The A molecular marker
ES2274977T3 (en) * 2001-05-03 2007-06-01 N.V. Organon PEPTIDYLARGININE DEIMINASE 6.
US7157558B2 (en) 2001-06-01 2007-01-02 Genentech, Inc. Polypeptide encoded by a polynucleotide overexpresses in tumors
CA2489623A1 (en) 2001-06-21 2003-01-03 Isis Innovation Limited Atopy
AU2002326429B2 (en) 2001-07-20 2007-09-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Phenylthiocarbamide (PTC) taste receptor
US7833779B2 (en) 2001-07-25 2010-11-16 Jivan Biologies Inc. Methods and systems for polynucleotide detection
US7340349B2 (en) 2001-07-25 2008-03-04 Jonathan Bingham Method and system for identifying splice variants of a gene
EP1417224A4 (en) * 2001-08-17 2005-08-10 Incyte Genomics Inc Secreted proteins
JP2005504546A (en) * 2001-08-17 2005-02-17 インサイト・ゲノミックス・インコーポレイテッド Intracellular signaling molecules
AU2002332929A1 (en) 2001-09-07 2003-03-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy39
WO2003025168A1 (en) * 2001-09-17 2003-03-27 Takeda Chemical Industries, Ltd. Novel protein and dna thereof
JP2005504534A (en) 2001-09-19 2005-02-17 アメリカ合衆国政府 Transductin-1 and transductin-2 and application to hereditary hearing impairment
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US8124052B2 (en) * 2003-02-10 2012-02-28 Georgetown University Method for identifying targeting domains and methods and compositions comprising the same
CA2476518A1 (en) * 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7642242B2 (en) 2002-03-05 2010-01-05 Genentech, Inc. PRO34128 polypeptides
JP2005518820A (en) * 2002-03-05 2005-06-30 ジェネンテック・インコーポレーテッド Novel polypeptide having sequence similarity to GDNFR and nucleic acid encoding the same
DE10211088A1 (en) 2002-03-13 2003-09-25 Ugur Sahin Gene products differentially expressed in tumors and their use
DK2258872T3 (en) 2002-03-13 2013-11-18 Genomic Health Inc Gene expression profiling in tumor tissue biopsies
AU2003220920B2 (en) * 2002-03-14 2008-11-06 National Institute Of Advanced Industrial Science And Technology Novel N-Acetylglucosamine transferase, nucleic acid encoding the same and use thereof in diagnosing cancer and / or tumor
AU2003231088B2 (en) * 2002-04-23 2008-05-22 University Of Georgia Research Foundation, Inc. N-acetylglucosaminyltransferase Vb coding sequence, recombinant cells and methods
WO2003104394A2 (en) * 2002-05-21 2003-12-18 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon
WO2003101401A2 (en) 2002-06-03 2003-12-11 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
IL165669A0 (en) * 2002-07-29 2006-01-15 Senomyx Inc Identification of a novel bitter taste receptor t2r76
WO2004013347A2 (en) * 2002-08-06 2004-02-12 Curagen Corporation Methods of identifying compounds that modulate protein activity
JP4186004B2 (en) * 2002-08-14 2008-11-26 独立行政法人産業技術総合研究所 Novel N-acetylgalactosamine transferase and nucleic acid encoding the same
WO2004024914A1 (en) * 2002-09-13 2004-03-25 Sankyo Company, Limited 2’,5’-oligoadenylate phosphodiesterase
AU2003291625B2 (en) * 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2003275173A1 (en) * 2002-09-25 2004-04-19 Board Of Regents, The University Of Texas System Endogenous granzyme b in human non-hematopoietic cells
US7700108B2 (en) * 2002-09-27 2010-04-20 Dainippon Sumitomo Pharma Co., Ltd. Tumor antigen protein and use thereof
CA2500472A1 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
EP1558737A4 (en) * 2002-10-18 2008-06-11 Lg Life Sciences Ltd Gene families associated with cancers
GB0224436D0 (en) * 2002-10-21 2002-11-27 Univ Cambridge Tech Polypetides methods and means
WO2004039956A2 (en) * 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7288642B1 (en) 2002-11-07 2007-10-30 Mayo Foundation For Medical Education And Research Sulfotransferase 2B1 pharmacogenetics
EP1570080A4 (en) 2002-11-15 2006-03-01 Genomic Health Inc Gene expression profiling of egfr positive cancer
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
GB0227908D0 (en) * 2002-11-29 2003-01-08 Univ London Cancer related methods and means
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
AU2007231823B2 (en) * 2003-01-24 2011-07-21 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254P1D6B useful in treatment and detection of cancer
WO2004067716A2 (en) 2003-01-24 2004-08-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
WO2004071269A2 (en) * 2003-02-13 2004-08-26 Intellectual Property Consulting Inc. Gene marker and composition for diagnosis and treatment of neurological disorders and diseases and use of the same
EP1597391B1 (en) 2003-02-20 2008-10-29 Genomic Health, Inc. Use of intronic rna to measure gene expression
US7312197B2 (en) 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
WO2004081170A2 (en) * 2003-03-10 2004-09-23 Ares Trading S.A. Progestin receptor-like protein
EP1606409B1 (en) 2003-03-19 2010-09-01 Biogen Idec MA Inc. Nogo receptor binding protein
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
WO2004087748A1 (en) * 2003-04-04 2004-10-14 Centre National De La Recherche Scientifique Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
FR2854640A1 (en) * 2003-05-07 2004-11-12 Galderma Res & Dev Use of polynucleotide probe specific for the PMP 69 gene in diagnosis of psoriasis and to screen for antipsoriatic agents, also therapeutic use by inhibiting PMP 69 expression or activity
US20050164218A1 (en) * 2003-05-30 2005-07-28 David Agus Gene expression markers for response to EGFR inhibitor drugs
AU2004258071A1 (en) 2003-06-19 2005-01-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants of human taste receptor genes
EP3170906B1 (en) 2003-06-24 2018-08-22 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
WO2005044977A2 (en) * 2003-06-25 2005-05-19 Diadexus, Inc. Compositions, splice variants and methods relating to lung specific genes and proteins
CA2530672A1 (en) * 2003-06-27 2005-01-06 Seikagaku Corporation Method of detecting cancer
WO2005008213A2 (en) 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
DE10332854A1 (en) * 2003-07-18 2005-02-17 Universitätsklinikum der Charité der Humboldt-Universität zu Berlin Use of the newly identified human gene 7a5 / prognostin for tumor diagnostics and tumor therapy
US20070037204A1 (en) 2003-08-08 2007-02-15 Hiroyuki ABURANTAI Gene overexpressed in cancer
EP1652923B1 (en) * 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene overexpressed in cancer
AU2003275958A1 (en) * 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US20050089899A1 (en) * 2003-08-28 2005-04-28 Daniel Birnbaum Identification of an ERBB2 gene expression signature in breast cancers
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
DE10341812A1 (en) * 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
DE10345010A1 (en) * 2003-09-22 2005-04-28 Eike Staub Use of the receptor Nifie14, or nucleic acid encoding it, for detecting cancer, or the risk of developing it, also use of Nifie 14 binding agents for diagnosis and treatment of cancer
DE10344799A1 (en) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
GB0322998D0 (en) * 2003-10-01 2003-11-05 Ares Trading Sa Protein
WO2005051994A2 (en) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Ztnf11, a tumor necrosis factor
EP1711622A2 (en) * 2003-11-26 2006-10-18 Applera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US20070218460A1 (en) * 2003-11-27 2007-09-20 Takeda Pharmaceutical Company Limited Method of Estimating Toxicity of Drug
AU2004294527A1 (en) * 2003-12-05 2005-06-16 Erasmus Mc Predicting response and outcome of metastatic breast cancer anti-estrogen therapy
WO2005064019A2 (en) 2003-12-23 2005-07-14 Genomic Health, Inc. Universal amplification of fragmented rna
WO2005066363A2 (en) * 2004-01-09 2005-07-21 Medigen Biotechnology Corporation Cancer specific gene ccndbp1
WO2005076014A1 (en) * 2004-01-28 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human metabotropic glutamate receptor 2 (mglur2)
EP1711633A1 (en) * 2004-02-04 2006-10-18 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of the kcne4 gene and protein for alzheimer disease
JP5830213B2 (en) 2004-02-17 2015-12-09 ザ ホスピタル フォー シック チルドレン MECP2E1 gene
US8637236B2 (en) 2004-02-17 2014-01-28 The Hospital For Sick Children MECP2E1 gene
WO2005078444A1 (en) * 2004-02-18 2005-08-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human melatonin receptor type 1b (mtnr1b)
WO2005083437A1 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with integrin-linked kinase 2 (ilk2)
US7166433B2 (en) * 2004-03-03 2007-01-23 The United States Of America As Represented By The Department Of Health And Human Services Transductin-1 and transductin-2 and applications to hereditary deafness
EP1786833A4 (en) 2004-03-19 2009-02-25 Univ Yale Detection, isolation and uses of renalase (monoamine oxidase c)
WO2005090569A1 (en) * 2004-03-24 2005-09-29 The Council Of The Queensland Institute Of Medical Research Cancer and testis vsm1 and vsm2 nucleic acids, proteins and uses thereof
JP4746537B2 (en) 2004-03-31 2011-08-10 第一三共株式会社 Gene encoding guanine nucleotide exchange factor and gene product thereof
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
ES2353604T3 (en) 2004-04-20 2011-03-03 Galapagos N.V. METHODS, COMPOSITIONS AND COMPOUND TESTS TO INHIBIT THE PRODUCTION OF BETA-AMILOID PROTEIN.
ES2687786T3 (en) * 2004-04-21 2018-10-29 Alexion Pharmaceuticals, Inc. Conjugates for bone administration and their use procedure to direct proteins to bone
EP1745292A2 (en) 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
EP1766042A2 (en) * 2004-05-21 2007-03-28 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with chymase (cma1)
CA2565524A1 (en) * 2004-06-04 2005-12-15 Applied Research Systems Ars Holding N.V. Splice variant of unc5h2
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8034553B2 (en) * 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
JP4960865B2 (en) 2004-06-24 2012-06-27 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment of conditions related to demyelination
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
US20060008876A1 (en) 2004-07-07 2006-01-12 Shami A S E ME-5, ME-2, and EPP2: human protein antigens reactive with autoantibodies present in the serum of women suffering from endometriosis
US20070264277A1 (en) * 2004-07-22 2007-11-15 Dirk Behrens Compositions and Methods of Use for Mgd-Csf in Disease Treatment
WO2006010516A1 (en) * 2004-07-29 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 like protein (metap2-like)
WO2006022689A1 (en) * 2004-08-06 2006-03-02 Applera Corporation Method and compositions for treating diseases targeting cd51
GB0417887D0 (en) 2004-08-11 2004-09-15 Ares Trading Sa Protein
EP1807540A4 (en) * 2004-11-05 2008-12-10 Us Gov Sec Navy Diagnosis and prognosis of infectious diesease clinical phenotypes and other physiologic states using host gene expresion biomarkers in blood
PL1836629T3 (en) 2004-11-05 2020-06-15 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
ATE550440T1 (en) 2004-11-05 2012-04-15 Genomic Health Inc MOLECULAR INDICATORS FOR BREAST CANCER PROGNOSIS AND PREDICTION OF TREATMENT RESPONSE
WO2006082826A1 (en) * 2005-02-02 2006-08-10 Eisai R & D Management Co., Ltd. METHOD OF IDENTIFYING PURKINJE CELL TARGETING Corl2 GENE
EP1851543A2 (en) 2005-02-24 2007-11-07 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
DE102005013846A1 (en) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
KR101245462B1 (en) 2005-07-08 2013-03-20 바이오겐 아이덱 엠에이 인코포레이티드 Sp35 antibodies and uses thereof
GB0515180D0 (en) * 2005-07-22 2005-08-31 Ares Trading Sa Protein
WO2007021807A1 (en) 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
US7488582B2 (en) * 2005-11-02 2009-02-10 Stowers Institute For Medical Research Nucleic acids and associated diagnostics
AU2006315299A1 (en) 2005-11-21 2007-05-24 Yale University Methods of regulating renalase (Monoamine Oxidase C)
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
GB0524648D0 (en) * 2005-12-02 2006-01-11 Ares Trading Sa Reeler domain containing protein
GB0524984D0 (en) * 2005-12-07 2006-01-18 Ares Trading Sa Cys-rich, cell surface glycoproteins
GB0525958D0 (en) * 2005-12-20 2006-02-01 Ares Trading Sa Casein-like secreted protein
US7723052B2 (en) 2006-05-11 2010-05-25 Quark Pharmaceuticals, Inc. Screening systems utilizing RTP801
EP2026843A4 (en) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc Therapeutic uses of inhibitors of rtp801l
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
PL2044111T3 (en) 2006-06-21 2015-02-27 Musc Found For Res Dev Targeting complement factor h for treatment of diseases
KR100873382B1 (en) 2006-12-21 2008-12-10 김현기 Human protooncogene, protein encoded by same, expression vector containing same, and cell transformed by said vector
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
WO2008106709A1 (en) * 2007-03-07 2008-09-12 The Council Of The Queensland Institute Of Medical Research NOVEL HUMAN ssDNA BINDING PROTEINS AND METHODS OF CANCER DIAGNOSIS
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
US8163709B2 (en) 2008-01-28 2012-04-24 Board Of Regents Of The University Of Texas System TAK1-D mediated induction of cell death in human cancer cells by specific sequence short double-stranded RNAS
US7833721B2 (en) 2008-03-14 2010-11-16 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome
WO2009134709A2 (en) * 2008-04-28 2009-11-05 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
EP2133433A1 (en) * 2008-06-09 2009-12-16 Centre Georges François Leclerc A method for predicting responsiveness to a treatment with an anti-HER2 antibody
CN102131939B (en) * 2008-06-25 2015-08-26 韩国巴斯德研究所 The full-length genome visual assessment of people's cofactor that HIV-1 infects
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
WO2010022145A2 (en) * 2008-08-19 2010-02-25 The University Of North Carolina At Chapel Hill Alternatively-spliced isoform of mu-opioid receptor gene with cell excitatory function
KR20120000056A (en) * 2009-02-11 2012-01-03 고쿠리츠다이가쿠호우진 도쿄다이가쿠 Brain tumor stem cell differentiation promoter, and therapeutic agent for brain tumor
DK3255146T3 (en) 2009-03-16 2019-08-19 Pangu Biopharma Ltd Compositions and Methods comprising Histidyl-tRNA Synthetase Splicing Variants with Non-Canonical Biological Activities
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
WO2010151664A2 (en) 2009-06-26 2010-12-29 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
US8435961B2 (en) 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
EP2453906A4 (en) 2009-07-02 2014-01-15 Musc Found For Res Dev Methods of stimulating liver regeneration
CN102958535A (en) 2009-11-05 2013-03-06 亚力史剑桥公司 Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
PT105029B (en) * 2010-03-29 2012-09-11 Univ Do Minho NUCLEIC PEPTIDE ACID PROBE, CASE AND METHOD FOR DETECTING AND / OR QUANTIFYING SALMONELLA AND THEIR APPLICATIONS
US10619195B2 (en) 2010-04-06 2020-04-14 Massachusetts Institute Of Technology Gene-expression profiling with reduced numbers of transcript measurements
CN103168118A (en) * 2010-04-06 2013-06-19 麻省理工学院 Gene-expression profiling with reduced numbers of transcript measurements
JP5986986B2 (en) 2010-04-30 2016-09-06 アレクシオン ファーマシューティカルズ， インコーポレイテッド Methods, compositions and kits for treating substrate calcification disorders
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
CN103038252A (en) 2010-05-14 2013-04-10 科罗拉多大学董事会,法人团体 Improved complement receptor 2 (CR2) targeting groups
AU2011270959A1 (en) 2010-06-22 2013-01-10 Musc Foundation For Research Development Antibodies to the C3d fragment of complement component 3
JP2013541938A (en) * 2010-09-02 2013-11-21 プロビオドルグ エージー In vivo screening model for the treatment of isoQC related disorders
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
AU2012257779A1 (en) 2011-05-16 2013-11-28 Bayer Intellectual Property Gmbh Use of cathepsin K inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
EP2780472A4 (en) * 2011-11-15 2015-10-28 Oncocyte Corp Methods and compositions for the treatment and diagnosis of bladder cancer
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
CN104470541A (en) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 Lingo-2 antagonists for treatment of conditions involving motor neurons
JO3623B1 (en) 2012-05-18 2020-08-27 Amgen Inc St2 antigen binding proteins
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014018849A1 (en) * 2012-07-26 2014-01-30 International Park Of Creativity Preparation of biological devices and their use thereof for increasing the production of secondary metabolites from plants
WO2014018822A2 (en) 2012-07-26 2014-01-30 Casa Luker S.A. Methods for increasing the production of phenolic compounds from theobroma cacao
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
CN104178489B (en) * 2013-05-23 2017-09-19 安徽医科大学第一附属医院 AAGAB gene mutation bodies and its application
US20170130272A1 (en) * 2014-05-21 2017-05-11 Consiglio Nazionale Delle Ricerche A Diagnostic Marker For Paget's Disease
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
US10449236B2 (en) 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
RU2745528C2 (en) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Production of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11111279B2 (en) 2015-11-20 2021-09-07 Grand Valley State University Nato3 mutant polypeptides and uses thereof
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20220162816A (en) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 Treating muscle weakness with alkaline phosphatases
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (en) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to treat bronchomalacia
MX2019011508A (en) 2017-03-31 2019-11-01 Alexion Pharma Inc Methods for treating hypophosphatasia (hpp) in adults and adolescents.
JP2020517638A (en) 2017-04-20 2020-06-18 エータイアー ファーマ， インコーポレイテッド Compositions and methods for treating lung inflammation
WO2019036484A1 (en) * 2017-08-15 2019-02-21 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of argininosuccinic aciduria
CN110172462B (en) * 2017-08-20 2021-11-30 浙江大学 Gene with promotion effect on generation and development of tumor, expression product and application thereof
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021265A1 (en) * 1994-02-01 1995-08-10 Isis Innovation Limited Methods for discovering ligands

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021265A1 (en) * 1994-02-01 1995-08-10 Isis Innovation Limited Methods for discovering ligands

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURGE C ET AL: "Prediction of complete gene structure in human genomic DNA", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 268, no. 1, 25 April 1997 (1997-04-25), pages 78 - 94, XP002109301, ISSN: 0022-2836 *
MIYAJIMA NOBUYUKI ET AL: "Computational and experimental analysis identifies many novel human genes.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 272, no. 3, 16 June 2000 (2000-06-16), pages 801 - 807, XP002243508, ISSN: 0006-291X *
SOLOVYEV VICTOR V ET AL: "Predicting internal exons by oligonucleotide composition and discriminant analysis of spliceable open reading frames.", NUCLEIC ACIDS RESEARCH, vol. 22, no. 24, 1994, pages 5156 - 5163, XP002915964, ISSN: 0305-1048 *
ZHU TONG ET AL: "Large-scale profiling of the Arabidopsis transcriptome.", PLANT PHYSIOLOGY (ROCKVILLE), vol. 124, no. 4, December 2000 (2000-12-01), pages 1472 - 1476, XP002243507, ISSN: 0032-0889 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101061016B1 (en) 2008-09-17 2011-08-31 강원대학교산학협력단 Polypeptides or fusion proteins thereof having an inhibitory activity against growth of cancer cells and preventive or treating activity against inflammatory diseases
KR101062167B1 (en) 2008-10-23 2011-09-05 사회복지법인 삼성생명공익재단 A composition for treating cancer comprising a Vir 2.2 inhibitor
US9127268B2 (en) 2009-12-11 2015-09-08 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US9328340B2 (en) 2009-12-11 2016-05-03 Atyr Pharma, Inc. Amino acyl tRNA synthetases for modulating inflammation
US9540628B2 (en) 2009-12-11 2017-01-10 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9273302B2 (en) 2012-02-16 2016-03-01 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates

Also Published As

Publication number Publication date
WO2002068579A2 (en) 2002-09-06
AU2002255478A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
WO2002068579A3 (en) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
WO2001071042A3 (en) Detection kits, such as nucleic acid arrays, for detecting the expression of 10,000 or more drosophila genes and uses thereof
EP1591541A3 (en) Method of nucleic acid sequencing
WO2002002806A3 (en) Method and nucleic acids for analysing the methylation of genes implicated in pharmacogenomics
WO2001077376A3 (en) Diagnosis of diseases associated with metastasis
WO2001068911A3 (en) Diagnosis of diseases associated with the cell cycle
WO2000079009A3 (en) Improved primers and methods for the detection and discrimination of nucleic acids
WO1999049082A3 (en) Modified nucleotides and methods useful for nucleic acid sequencing
EP3040423A3 (en) Microrna and uses thereof
GB0317343D0 (en) Polynucleotide sequencing
WO2002057479A3 (en) Primers and methods for the detection and discrimination of nucleic acids
WO2005003386A3 (en) Oligonucleotide ligation assay by detecting released pyrophosphate
WO2002010209A8 (en) Nucleotide sequences which code for the meth gene
AU2003211947A1 (en) PRIMERS FOR NUCLEIC ACID AMPLIFICATION IN DETECTING HOUSEKEEPING GENE mRNA AND TEST METHOD USING THESE PRIMERS
WO2002036828A3 (en) COMPOSITIONS AND SYSTEMS FOR IDENTIFYING AND COMPARING EXPRESSED GENES (mRNAs) IN EUKARYOTIC ORGANISMS
WO2001038351A3 (en) Nucleotide sequence of the shrimp white spot syndrome bacilliformvirus (wsbv), systems containing this sequence and detection kits
AU2003234932A1 (en) Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
WO2000003013A3 (en) Gene and protein involved in liver regeneration
ATE356210T1 (en) NUCLEOTIDE SEQUENCES ENCODING THE GLBO GENE FROM CORYNEBACTERIUM GLUTAMICUM
EP1580265A4 (en) Nucleic acids isolated from neuroblastoma at stage 4s
WO2004099443A3 (en) Method for selection of optimal microarray probes
WO2001051670A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP